A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07502014 by Huazhong University of Science and Technology, with a registry enrolment figure of 60 participants, started 2026-05-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Iparomlimab and Tuvonralimab (QL1706); Fruquintinib; Heterogeneous Radiotherapy. Conditions listed: Metastatic Colorectal Cancer (CRC); mCRC. Primary outcome: Progression-Free Survival. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed stage Ⅳ primary colorectal cancer". No results are recorded here; the registry entry is the source.